# Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin

> **NCT06031454** · PHASE1 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 56 (actual)

## Conditions studied

- Drug Drug Interaction

## Interventions

- **DRUG:** Midazolam
- **DRUG:** Omeprazole
- **DRUG:** Rosuvastatin
- **DRUG:** Verapamil
- **DRUG:** Rifampin
- **DRUG:** Leritrelvir

## Key facts

- **NCT ID:** NCT06031454
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031454, "Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06031454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*